IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 7.2% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings is a company facing challenges in revenue growth, with concerns about market share pressure and softer demand in the data-driven pharma enablement sector. Despite these challenges, the stock experienced a bullish movement today.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 7.2% on Jun 24, 2026 16:41

• IQVIA Holdings stock rose by 2.07% despite underperforming compared to competitors and amidst a generally grim trading session for the S&P 500 Index and the Dow Jones Industrial Average.
• The company's recent move to raise $950 million in new senior notes to refinance existing debt might have influenced investor sentiment positively, showing efforts to manage balance sheet flexibility.
• The technical analysis indicating a "Sell" signal based on price momentum score, support/resistance levels, and moving averages could have created short-term trading opportunities for investors looking to capitalize on the stock's range-bound movement.
• Overall, IQVIA's ability to navigate growth challenges, balance debt refinancing, and maintain investor confidence in its strategic investments in AI and data platforms could be key factors impacting its stock performance in the near future.

IQV Price Chart

IQV Technical Analysis

IQV News

HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why

HSBC recently cut its price target on Danaher Corporation (DHR) to $230 from $270 but maintained a Buy rating, citing bearish market expectations for life science tools despite "green shoots of recovery" in bioprocessing. Separately, Wolfe Research downgraded DHR to Peer Perform, noting its valuation compared to Thermo Fisher and confusion regarding its identity after the Masimo transaction. Danaher, a significant diagnostics stock, operates across various scientific and industrial sectors.

https://www.insidermonkey.com/blog/hsbc-cuts-pt-on-danaher-corporation-dhr-heres-why-1787152/?amp=1

Does Slower Growth at IQVIA Holdings (IQV) Challenge Its Core Data‑Driven Pharma Enablement Story?

IQVIA Holdings is facing growth challenges, with revenue increases lagging peers and constant-currency trends indicating softer demand and market share pressure. This situation creates tension between IQVIA’s role in drug development and commercialization and its current struggle for stronger growth momentum. The company's recent move to raise US$950 million in new senior notes to refinance existing debt is particularly relevant, and its ability to manage refinancing, interest costs, and balance sheet flexibility will influence how investors perceive its trade-off between slower revenue growth, buybacks, and investments in AI and data platforms.

https://ca.finance.yahoo.com/news/does-slower-growth-iqvia-holdings-020953117.html

IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Shares of IQVIA Holdings Inc. (IQV) rose by 2.07% on Tuesday, closing at $171.28. Despite this daily gain, the stock underperformed compared to its competitors as both the S&P 500 Index and the Dow Jones Industrial Average experienced declines. This marks the second consecutive day of gains for IQVIA Holdings Inc. amidst a generally grim trading session.

https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-tuesday-when-compared-to-competitors-despite-daily-gains-8f0b19ce-94f731cc704d?mod=mw_quote_news

IQVIA Holdings Inc (IQV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of IQVIA Holdings Inc (IQV), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes that IQV's price momentum score is 6.76, suggesting suitability for range-bound swing trading between $156.15 and $185.08. The analysis concludes with a strong "Sell" signal based on the compiled technical indicators and moving averages.

https://www.tradingkey.com/markets/stocks/nasdaq-iqv/technical

How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Charles River Laboratories International, Inc. (CRL) is a mid-cap healthcare company providing non-clinical drug development services. While CRL's shares have outperformed the State Street Health Care Select Sector SPDR ETF (XLV) over the past three months, it has lagged XLV over the past 52 weeks and year-to-date. Analysts remain optimistic about CRL, with a "Strong Buy" consensus rating and a price target suggesting an 18.3% upside from current levels, boosted by a recent Morgan Stanley upgrade.

https://www.barchart.com/story/news/2581000/how-is-charles-river-laboratories-stock-performance-compared-to-other-health-care-stocks

Trending Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.5% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.6% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Up 6.7% Today

Ambarella Inc. ($AMBA) Stock Forecast: Down 5.5% Today

PulteGroup Inc. ($PHM) Stock Forecast: Up 7.9% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Up 6.2% Today

Oracle Corporation ($ORCL) Stock Forecast: Down 6.9% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 5.1% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Down 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Down 5.2% Today

IQVIA Holdings Inc. Price History

18.05.2026 - IQV Stock was down 5.2%

• Despite a positive earnings forecast and analyst ratings, IQV's stock experienced a bearish trend, indicating potential profit-taking by investors.
• The strong shareholder structure and institutional holdings may not have been enough to offset broader market sentiment impacting IQV's stock price.
• It's possible that external factors, such as overall market volatility or sector rotation, contributed to the bearish movement in IQV's stock, overshadowing the positive forecasts and ratings.

04.05.2026 - IQV Stock was up 6.0%

• A recent price target adjustment and maintained Buy rating on IQV by HSBC indicate confidence in the company's long-term prospects, despite the revised target.
• IQVIA's plan to raise €950 million through senior notes to refinance debt highlights a strategic move to optimize its capital structure and enhance financial flexibility.
• The market responded positively to these recent developments, resulting in a bullish movement in IQV's stock as investors perceive the refinancing as a positive step towards long-term growth and innovation in the life sciences sector.

04.05.2026 - IQV Stock was up 6.1%

• IQVIA's decision to price senior notes due 2033 with a 4.625% interest rate is viewed as a strategic step to manage its existing debt more effectively, resonating well with investors.
• The successful pricing of the senior notes indicates a strong investor confidence in IQVIA's financial strategies and debt management capabilities.
• Despite HSBC revising the price target for IQVIA while upholding a Buy rating, the overall sentiment remains optimistic, contributing to the positive momentum in the company's stock.
• By opting to offer senior notes for refinancing purposes, IQVIA is displaying a proactive approach towards optimizing its capital structure, which could potentially bolster its long-term financial health and growth opportunities.

24.05.2026 - IQV Stock was up 7.1%

• Despite facing growth challenges and revenue lagging behind peers, IQVIA Holdings Inc. (IQV) managed to soar by 2.07% on Tuesday.
• The company's recent move to raise $950 million in new senior notes to refinance existing debt might have instilled confidence in investors, contributing to the bullish momentum.
• IQV's ability to balance slower revenue growth with investments in AI and data platforms could be seen as a strategic move that resonated positively with the market, leading to the stock outperforming amidst a generally grim trading session.
• The technical analysis indicating a "Sell" signal based on compiled indicators and moving averages did not seem to deter investors, highlighting the resilience and potential perceived value in IQVIA Holdings Inc.

03.05.2026 - IQV Stock was down 5.2%

• A notable reduction in the price target from $240 to $210 by HSBC, despite affirming a Buy rating, may have triggered investor uncertainty and resultant stock selling pressure.
• IQVIA's subsidiaries' publicizing of senior notes offerings could have sparked worries about heightened debt levels and potential shareholder value dilution, contributing to the negative market sentiment.
• The company surpassed expectations in Q1 2026 earnings and revenue and bolstered partnerships. However, the perception of being undervalued according to InvestingPro analysis did not counterbalance the negative impact of the debt offerings on stock performance.
• The combined factors of a reduced price target, debt refinancing strategies, and market dynamics linked to the senior notes offerings likely played roles in today's decline in IQV's stock.

05.04.2026 - IQV Stock was up 10.0%

• IQVIA reported strong first-quarter 2026 financial results, with revenue increasing by 8.4% year-over-year to $4,151 million and Adjusted Diluted Earnings per Share up by 7.4%. This positive performance was driven by strong results in both Commercial Solutions and Research & Development Solutions.
• Despite exceeding earnings and revenue forecasts, the stock initially dipped in pre-market trading due to investor concerns. This could be attributed to market volatility and increased competition in the industry.
• IQVIA's strong performance was fueled by AI solutions, new drug launches, and strategic partnerships, along with aggressive share repurchases. The company's focus on innovation and growth strategies seems to be resonating well with investors, leading to a bullish market movement for the stock.

24.05.2026 - IQV Stock was up 7.2%

• IQVIA Holdings stock rose by 2.07% despite underperforming compared to competitors and amidst a generally grim trading session for the S&P 500 Index and the Dow Jones Industrial Average.
• The company's recent move to raise $950 million in new senior notes to refinance existing debt might have influenced investor sentiment positively, showing efforts to manage balance sheet flexibility.
• The technical analysis indicating a "Sell" signal based on price momentum score, support/resistance levels, and moving averages could have created short-term trading opportunities for investors looking to capitalize on the stock's range-bound movement.
• Overall, IQVIA's ability to navigate growth challenges, balance debt refinancing, and maintain investor confidence in its strategic investments in AI and data platforms could be key factors impacting its stock performance in the near future.

05.04.2026 - IQV Stock was up 5.2%

• IQVIA reported strong first-quarter 2026 financial results, exceeding revenue and earnings expectations, driven by robust performance in Commercial Solutions and Research & Development Solutions.
• Despite beating forecasts and reaffirming its full-year guidance, IQV's stock initially dipped in pre-market trading due to investor concerns, possibly related to market volatility and competition worries.
• The market movement turned bullish as investors likely recognized the company's strong fundamentals, including its AI solutions, new drug launches, and strategic partnerships, leading to a positive outlook for continued growth.
• Integration of AI in life sciences operations, as highlighted in industry reports, could have also positively influenced investor sentiment towards IQVIA, showcasing the company's innovative approach and potential for further advancements in the sector.

06.04.2026 - IQV Stock was up 11.2%

• IQVIA reported strong Q1 2026 financial results, with revenue reaching $4.15 billion, an 8.4% increase year-over-year, and EPS of $1.61, beating estimates.
• The stock surged by 9.60% on May 5, driven by the company's robust performance across its segments and exceeding earnings and revenue expectations.
• Analysts maintain a positive outlook on IQV, citing AI as a key driver for its success, despite some technical sell signals and debt concerns.
• The market responded positively to IQV's strong trading day, outperforming competitors and reflecting overall bullish sentiment towards the stock.

28.04.2026 - IQV Stock was up 7.5%

• IQVIA Holdings Inc. experienced a significant 5.7% surge in its stock price, outperforming its competitors and the broader market, indicating strong investor interest in the company.
• The bullish movement was part of a sector-wide rally in the diagnostics and research industry, with peers like Agilent Technologies and Thermo Fisher Scientific also posting notable gains.
• Analysts' bullish sentiments and positive outlook on IQVIA Holdings, citing factors such as expected revenue and earnings growth, a robust backlog, and strong demand driven by AI adoption, likely contributed to the stock's upward momentum.
• Investors should continue to monitor the sustainability of this rally and any further announcements from leading companies in the sector that could impact IQV's performance.

28.04.2026 - IQV Stock was up 5.5%

• IQVIA Holdings Inc. (IQV) stock outperformed its competitors and the broader market, breaking a four-day losing streak, fueled by strong trading activity.
• Analysts' bullish sentiments and optimistic price targets for IQV indicate confidence in the company's growth prospects, driven by factors such as strong demand from AI adoption and an active share repurchase program.
• The positive outlook for IQVIA Holdings Inc. (IQV) reflects investors' confidence in the company's revenue and earnings growth potential in the coming years, despite concerns about its weak liquidity profile and lack of dividend payments.

20.04.2026 - IQV Stock was down 5.7%

• The bearish movement in IQV's stock could be linked to CFRA downgrading its rating on the shares from Buy to Hold, potentially creating investor uncertainty and selling pressure.
• Despite IQVIA's strong Q1 earnings showing data strength and AI ambitions, the market reaction might have been influenced by the moderation in the stock rating, causing a shift in investor sentiment.
• The announcement of Labcorp's new AI-powered app for lab results interpretation could have negatively impacted IQV's stock, as investors may perceive increased competition or technological advancements in the healthcare data analytics field.
• IQVIA's decision to significantly increase its share repurchase program signals confidence in its financial health and future growth prospects, but the market might be reacting cautiously to this move amidst broader market uncertainties and the recent rating downgrade.